GSK expects to have four key cancer drugs in final-stage clinical trials next year, it said on Wednesday.
Europe's biggest drug maker said the four drugs -- Tykerb, formerly known as lapatinib, eltrombopag, casopitant and pazopanib -- all held promise for fighting tumours or helping patients overcome the side-effects of chemotherapy.
Until now, oncology has been a small area for Glaxo but the group believes new products will make it a major player in the fast-growing world of cancer medicine.
Insiders view: let's see what their presentation to city analysts later this week is made of. To move into a new disease area is very expensive. Rep recruitment and training is a major cost. Perhaps they need to consider a merger or takeover of a pharma company who already has a foothold in this area?
Source: Reuters
No comments:
Post a Comment